CAV1 and Alzheimer disease: Increased expression of caveolin-1 potentially reduces Aβ; caveolin-1 is also diminished in AD patients; it is affected by elevated blood glucose levels, which disrupt amyloid metabolism and increase tau phosphorylation [71].